Annual report pursuant to Section 13 and 15(d)

Consolidated Balance Sheets

v3.20.4
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 25,218 $ 85,451
Marketable securities, current 68,667 39,633
Prepaid expenses 6,080 2,318
Grants revenue receivable 0 7,100
Accounts receivable, related party 234 408
In-process research and development - held for sale 0 4,500
Other current assets 1,125 489
Total current assets 101,324 139,899
Marketable securities, non-current 0 1,510
Operating lease right-of-use assets 11,104 9,959
Property and equipment, net 22,254 18,158
Other assets 5,195 4,676
Total assets 139,877 174,202
Current liabilities:    
Accounts payable 2,350 1,465
Accrued liabilities 12,575 14,544
Deferred revenue, current 14,014 8,511
Deferred revenue, current, related party 789 8,780
Other current liabilities, related party 5,614 0
Other current liabilities 2,211 2,501
Total current liabilities 37,553 35,801
Deferred revenue, long-term 4,538 18,944
Deferred revenue, long-term, related party 3,106 441
Long-term debt, net 14,926 2,940
Operating lease liabilities 12,213 11,682
Other liabilities, related party 6,711 0
Other liabilities 1,490 1,366
Total liabilities 80,537 71,174
Commitments and contingencies (Note 10) 0 0
Stockholders’ equity    
Preferred stock, $0.001 par value: Authorized: 2,000,000 shares at December 31, 2020 and December 31, 2019; issued and outstanding: 250 shares at December 31, 2020 and December 31, 2019 0 0
Common stock, $0.001 par value: Authorized: 150,000,000 shares at December 31, 2020 and December 31, 2019; issued and outstanding: 49,984,333 shares at December 31, 2020 and 45,589,157 shares at December 31, 2019 50 46
Additional paid-in capital 328,314 267,089
Accumulated other comprehensive income 17 18
Accumulated deficit (269,041) (164,125)
Total stockholders’ equity 59,340 103,028
Total liabilities and stockholders’ equity $ 139,877 $ 174,202